In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Clover Health Investments Corp’s stock clocked out at $2.51, down -5.64% from its previous closing price of $2.66. In other words, the price has decreased by -$5.64 from its previous closing price. On the day, 6.79 million shares were traded. CLOV stock price reached its highest trading level at $2.68 during the session, while it also had its lowest trading level at $2.455.
Ratios:
To gain a deeper understanding of CLOV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cowen on February 02, 2022, Upgraded its rating to Market Perform and sets its target price to $3 from $7 previously.
On February 02, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $6.
On January 19, 2022, SVB Leerink started tracking the stock assigning a Mkt Perform rating and target price of $3.SVB Leerink initiated its Mkt Perform rating on January 19, 2022, with a $3 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 09 ’24 when Garipalli Vivek bought 531,700 shares for $1.88 per share. The transaction valued at 999,596 led to the insider holds 1,409,267 shares of the business.
Garipalli Vivek bought 877,567 shares of CLOV for $1,000,426 on Jun 17 ’24. The Director now owns 877,567 shares after completing the transaction at $1.14 per share. On May 16 ’24, another insider, Loengard Anna U, who serves as the Director of the company, bought 17,085 shares for $0.96 each. As a result, the insider paid 16,372 and bolstered with 15,600 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1248647168 and an Enterprise Value of 873604544. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.74 while its Price-to-Book (P/B) ratio in mrq is 3.72. Its current Enterprise Value per Revenue stands at 0.418 whereas that against EBITDA is -8.749.
Stock Price History:
Over the past 52 weeks, CLOV has reached a high of $3.82, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is 23.06%, while the 200-Day Moving Average is calculated to be 110.58%.
Shares Statistics:
It appears that CLOV traded 7.61M shares on average per day over the past three months and 11279260 shares per day over the past ten days. A total of 393.27M shares are outstanding, with a floating share count of 375.64M. Insiders hold about 24.49% of the company’s shares, while institutions hold 14.74% stake in the company. Shares short for CLOV as of 1723680000 were 29355068 with a Short Ratio of 3.86, compared to 1721001600 on 35079093. Therefore, it implies a Short% of Shares Outstanding of 29355068 and a Short% of Float of 7.31.
